TENX

SEC source: 0001193125-26-394831 · ownership.xml · nonDerivative · entry 1

Doogan Declan · CIK 0001704234 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,274

SEC source: 0001871714-26-000002 · primary_doc.xml · nonDerivative · entry 2

Giordano Christopher Thomas · CIK 0001871714 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,174

F2 · price: This transaction was executed in multiple trades at prices ranging from $1.82 to $1.83. The price reported in Column 4 is a weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

SEC source: 0001871714-26-000002 · primary_doc.xml · nonDerivative · entry 1

Giordano Christopher Thomas · CIK 0001871714 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,324

F1 · price: This transaction was executed in multiple trades at prices ranging from $1.87 to $1.88. The price reported in Column 4 is a weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

SEC source: 0001193125-26-392319 · ownership.xml · nonDerivative · entry 1

STAAB THOMAS R II · CIK 0001230708 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,675

F1 · price: This transaction was executed in multiple trades at prices ranging from $1.90 to $1.95. The price reported in Column 4 is a weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

SEC source: 0001940272-26-000020 · primary_doc.xml · nonDerivative · entry 1

ADAR1 Capital Management, LLC · CIK 0001940272 · 10% owner

Schneeberger Daniel · CIK 0001861120 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 6,524,151

F1 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.7800 to $1.8000, inclusive. Each Reporting Person undertakes to provide to Tenax Therapeutics, Inc., any security holder of Tenax Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

F2 · ownership.nature: The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC.

F3 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

SEC source: 0001940272-26-000019 · primary_doc.xml · nonDerivative · entry 3

ADAR1 Capital Management, LLC · CIK 0001940272 · 10% owner

Schneeberger Daniel · CIK 0001861120 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 5,624,151

F3 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.7750 to $1.8000, inclusive. Each Reporting Person undertakes to provide to Tenax Therapeutics, Inc., any security holder of Tenax Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

F4 · ownership.nature: The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC.

F5 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

SEC source: 0001940272-26-000019 · primary_doc.xml · nonDerivative · entry 2

ADAR1 Capital Management, LLC · CIK 0001940272 · 10% owner

Schneeberger Daniel · CIK 0001861120 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 5,436,447

F2 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.7700 to $1.8000, inclusive. Each Reporting Person undertakes to provide to Tenax Therapeutics, Inc., any security holder of Tenax Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

F4 · ownership.nature: The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC.

F5 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

SEC source: 0001940272-26-000019 · primary_doc.xml · nonDerivative · entry 1

ADAR1 Capital Management, LLC · CIK 0001940272 · 10% owner

Schneeberger Daniel · CIK 0001861120 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 5,257,389

F1 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.7700 to $1.8000, inclusive. Each Reporting Person undertakes to provide to Tenax Therapeutics, Inc., any security holder of Tenax Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

F4 · ownership.nature: The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC.

F5 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

SEC source: 0001940272-26-000017 · primary_doc.xml · nonDerivative · entry 3

ADAR1 Capital Management, LLC · CIK 0001940272 · 10% owner

Schneeberger Daniel · CIK 0001861120 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 4,853,818

F3 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.7000 to $1.8000, inclusive. Each Reporting Person undertakes to provide to Tenax Therapeutics, Inc., any security holder of Tenax Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

F4 · ownership.nature: The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC.

F5 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

SEC source: 0001940272-26-000017 · primary_doc.xml · nonDerivative · entry 2

ADAR1 Capital Management, LLC · CIK 0001940272 · 10% owner

Schneeberger Daniel · CIK 0001861120 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 4,746,444

F2 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.7250 to $1.8000, inclusive. Each Reporting Person undertakes to provide to Tenax Therapeutics, Inc., any security holder of Tenax Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

F4 · ownership.nature: The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC.

F5 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

SEC source: 0001940272-26-000017 · primary_doc.xml · nonDerivative · entry 1

ADAR1 Capital Management, LLC · CIK 0001940272 · 10% owner

Schneeberger Daniel · CIK 0001861120 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 4,030,075

F1 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.7650 to $1.8000, inclusive. Each Reporting Person undertakes to provide to Tenax Therapeutics, Inc., any security holder of Tenax Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

F4 · ownership.nature: The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC.

F5 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

SEC source: 0001193125-26-303600 · ownership.xml · derivative · entry 4

Giordano Christopher Thomas · CIK 0001871714 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,241,500

Underlying: Common Stock · 8,500 shares

Expires 2034-12-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001193125-26-303600 · ownership.xml · derivative · entry 3

Giordano Christopher Thomas · CIK 0001871714 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 218

Underlying: Common Stock · 219 shares

Expires 2034-05-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on each of May 17, 2025, May 17, 2026, May 17, 2027, and May 17, 2028, subject to the Reporting Person's continued employment.

SEC source: 0001193125-26-303600 · ownership.xml · nonDerivative · entry 2

Giordano Christopher Thomas · CIK 0001871714 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,324

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The aggregate exercise price was paid in cash.

SEC source: 0001193125-26-303600 · ownership.xml · nonDerivative · entry 1

Giordano Christopher Thomas · CIK 0001871714 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,824

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The aggregate exercise price was paid in cash.

SEC source: 0001193125-26-221926 · ownership.xml · derivative · entry 2

STAAB THOMAS R II · CIK 0001230708 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 450,000

Underlying: Common Stock · 450,000 shares

Expires 2036-05-11

F2 · derivative.exercise_date: The options vest and become exercisable as follows: 25% vest on May 11, 2027, and thereafter, the remainder vest in substantially equal installments on each monthly anniversary of the grant date for a period of 36 months, subject to the Reporting Person's continued employment.

SEC source: 0001193125-26-221926 · ownership.xml · nonDerivative · entry 1

STAAB THOMAS R II · CIK 0001230708 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,000

F1 · shares: Represents a restricted stock award which vests 25% ten days after the grant date, with the remainder vesting in three equal installments on the four-month, eight-month and twelve-month anniversaries of the grant date, subject to the Reporting Person's continued employment.

SEC source: 0001550701-26-000001 · primary_doc.xml · derivative · entry 4

MCGAULEY THOMAS · CIK 0001550701 · Interim CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2029-01-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The options vest and become exercisable with 50% vesting January 30, 2026 and 50% vesting on May 31, 2026, subject to the Reporting Person's continuous service to the Issuer.

SEC source: 0001573785-26-000001 · primary_doc.xml · derivative · entry 2

Davidson Michael H. · CIK 0001573785 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2036-01-09

SEC source: 0001871714-26-000001 · primary_doc.xml · derivative · entry 2

Giordano Christopher Thomas · CIK 0001871714 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 450,000

Underlying: Common Stock · 450,000 shares

Expires 2036-01-09

F1 · derivative.exercise_date: The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on January 9, 2027, and thereafter 1/36th of the remaining shares will vest on the last day of each following month for a period of 36 months, subject to the Reporting Person's continued employment.

SEC source: 0001841785-26-000001 · primary_doc.xml · derivative · entry 5

Rich Stuart · CIK 0001841785 · Director · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 250,000

Underlying: Common Stock · 250,000 shares

Expires 2036-01-09

F4 · derivative.exercise_date: The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on January 9, 2027, and thereafter 1/36th of the remaining shares will vest on the last day of each following month for a period of 36 months, subject to the Reporting Person's continued employment.

SEC source: 0001279191-26-000001 · primary_doc.xml · derivative · entry 2

PROEHL GERALD T · CIK 0001279191 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2036-01-09

SEC source: 0001492647-26-000001 · primary_doc.xml · derivative · entry 2

Almenoff June Sherie · CIK 0001492647 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2036-01-09

SEC source: 0001704234-26-000001 · primary_doc.xml · derivative · entry 2

Doogan Declan · CIK 0001704234 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2036-01-09

SEC source: 0001713932-26-000001 · primary_doc.xml · derivative · entry 1

Hunter Robyn · CIK 0001713932 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2036-01-09

SEC source: 0001841785-25-000004 · primary_doc.xml · nonDerivative · entry 2

Rich Stuart · CIK 0001841785 · Director · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,266

F3 · price: This transaction was executed in multiple trades at prices ranging from $9.70 to $10.45. The price reported in Column 4 is a weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

SEC source: 0001841785-25-000004 · primary_doc.xml · nonDerivative · entry 1

Rich Stuart · CIK 0001841785 · Director · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · By Stuart Rich Revocable Trust DTD 11/18/1996

Disclosed balance after: 5,000

F1 · price: This transaction was executed in multiple trades at prices ranging from $9.76 to $10.42. The price reported in Column 4 is a weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F2 · ownership.nature: The Reporting Person is trustee of the Stuart Rich Revocable Trust DTD 11/18/1996 and disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

SEC source: 0001841785-25-000003 · primary_doc.xml · nonDerivative · entry 3

Rich Stuart · CIK 0001841785 · Director · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · By Stuart Rich Revocable Trust DTD 11/18/1996

Disclosed balance after: 2,500

F3 · shares: This transaction was executed in multiple trades at prices ranging from $9.00 to $9.46. The price reported in Column 4 is a weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F4 · ownership.nature: The Reporting Person is trustee of the Stuart Rich Revocable Trust DTD 11/18/1996 and disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

SEC source: 0001841785-25-000003 · primary_doc.xml · nonDerivative · entry 2

Rich Stuart · CIK 0001841785 · Director · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,766

F2 · price: This transaction was executed in multiple trades at prices ranging from $8.88 to $9.22. The price reported in Column 4 is a weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

SEC source: 0001841785-25-000003 · primary_doc.xml · nonDerivative · entry 1

Rich Stuart · CIK 0001841785 · Director · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,266

F1 · price: This transaction was executed in multiple trades at prices ranging from $8.89 to $9.06. The price reported in Column 4 is a weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

SEC source: 0001871714-25-000002 · primary_doc.xml · nonDerivative · entry 3

Giordano Christopher Thomas · CIK 0001871714 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,605

F3 · price: This transaction was executed in multiple trades at prices ranging from $7.54 to $7.73. The price reported in Column 4 is a weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

SEC source: 0001871714-25-000002 · primary_doc.xml · nonDerivative · entry 2

Giordano Christopher Thomas · CIK 0001871714 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,067

F2 · price: This transaction was executed in multiple trades at prices ranging from $7.35 to $7.62. The price reported in Column 4 is a weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

SEC source: 0001492647-25-000003 · primary_doc.xml · nonDerivative · entry 2

Almenoff June Sherie · CIK 0001492647 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,993

F1 · price: This transaction was executed in multiple trades at prices ranging from $7.45 to $7.70. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

SEC source: 0001871714-25-000002 · primary_doc.xml · nonDerivative · entry 1

Giordano Christopher Thomas · CIK 0001871714 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,612

F1 · price: This transaction was executed in multiple trades at prices ranging from $7.47 to $7.68. The price reported in Column 4 is a weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

SEC source: 0001492647-25-000004 · primary_doc.xml · nonDerivative · entry 2

Almenoff June Sherie · CIK 0001492647 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Meadowlark Management, LLC

Disclosed balance after: 1,993

F2 · price: This transaction was executed in multiple trades at prices ranging from $7.45 to $7.70. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F1 · ownership.nature: The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein.

SEC source: 0001492647-25-000003 · primary_doc.xml · nonDerivative · entry 1

Almenoff June Sherie · CIK 0001492647 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 93

SEC source: 0001550701-25-000002 · primary_doc.xml · nonDerivative · entry 3

MCGAULEY THOMAS · CIK 0001550701 · Interim CFO

10b5-1 filing: No plan indicated

Ownership: Indirect · By Spouse

Disclosed balance after: 5,000

F2 · price: This transaction was executed in multiple trades at prices ranging from $7.17 to $7.30. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

SEC source: 0001550701-25-000002 · primary_doc.xml · nonDerivative · entry 2

MCGAULEY THOMAS · CIK 0001550701 · Interim CFO

10b5-1 filing: No plan indicated

Ownership: Indirect · By Child

Disclosed balance after: 1,000

SEC source: 0001550701-25-000002 · primary_doc.xml · nonDerivative · entry 1

MCGAULEY THOMAS · CIK 0001550701 · Interim CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,000

F1 · price: This transaction was executed in multiple trades at prices ranging from $7.14 to $7.43. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

SEC source: 0001492647-25-000004 · primary_doc.xml · nonDerivative · entry 1

Almenoff June Sherie · CIK 0001492647 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Meadowlark Management, LLC

Disclosed balance after: 93

F1 · ownership.nature: The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein.

SEC source: 0001654954-25-007739 · section16.xml · derivative · entry 1

Almenoff June Sherie · CIK 0001492647 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 80,000

Underlying: Common Stock · 80,000 shares

Expires 2035-07-01

SEC source: 0001654954-25-007738 · section16.xml · derivative · entry 2

Davidson Michael H. · CIK 0001573785 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 80,000

Underlying: Common Stock · 80,000 shares

Expires 2035-07-01

SEC source: 0001654954-25-007736 · section16.xml · derivative · entry 2

PROEHL GERALD T · CIK 0001279191 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 80,000

Underlying: Common Stock · 80,000 shares

Expires 2035-07-01

SEC source: 0001654954-25-007737 · section16.xml · derivative · entry 2

Doogan Declan · CIK 0001704234 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 80,000

Underlying: Common Stock · 80,000 shares

Expires 2035-07-01

SEC source: 0001654954-25-007734 · section16.xml · derivative · entry 1

Hunter Robyn · CIK 0001713932 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 80,000

Underlying: Common Stock · 80,000 shares

Expires 2035-07-01

SEC source: 0001654954-25-005950 · section16.xml · derivative · entry 4

Rich Stuart · CIK 0001841785 · Director · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 625,000

Underlying: Common Stock · 625,000 shares

Expires 2034-05-16

F3 · derivative.exercise_date: The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on May 16, 2026, and thereafter 1/36th of the remaining shares will vest on the last day of each following month for a period of 36 months, subject to the Reporting Person's continued employment.

SEC source: 0001654954-25-005949 · section16.xml · derivative · entry 1

Giordano Christopher Thomas · CIK 0001871714 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,400,000

Underlying: Common Stock · 1,400,000 shares

Expires 2035-05-16

F1 · derivative.exercise_date: The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on May 16, 2026, and thereafter 1/36th of the remaining shares will vest on the last day of each following month for a period of 36 months, subject to the Reporting Person's continued employment.

SEC source: 0001654954-24-015477 · section16.xml · derivative · entry 4

Rich Stuart · CIK 0001841785 · Director · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 500,000

Underlying: Common Stock · 500,000 shares

Expires 2034-12-10

SEC source: 0001654954-24-015475 · section16.xml · derivative · entry 1

Hunter Robyn · CIK 0001713932 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2034-12-10

SEC source: 0001654954-24-015476 · section16.xml · derivative · entry 2

PROEHL GERALD T · CIK 0001279191 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2034-12-10